Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Japan's Otsuka Pharmaceutical buys out Claris' 20% stake in JV for $ 20 mn

With this, Otsuka to strengthen its basic IV solution and clinical nutrition business in India

Rakesh Rao  |  Mumbai 

Claris' pharmaceutical products

Ahmedabad-based has entered into a definitive agreement to sell its 20 percent stake in India Pvt Ltd (formerly known as Claris Otsuka Pvt Ltd) to its joint venture partner, Factory Inc (OPF) of Japan, for a total consideration of $ 20 million (about Rs 129 crore). 

In July 2013, had transferred its business in India and emerging markets to the joint venture, Claris Otsuka. As per the terms of agreement, Claris held 20 percent stake in the joint venture, while and & Co Ltd owned 60 percent and 20 percent stake respectively. As part of the deal, two of the five plants of Claris were transferred to joint venture firm. 

Claris Otsuka Private Limited was rechristened as India Private Limited (OPI) on March 1, 2017.

“With this increase in the shareholdings of India, OPF will be able to maximise the utilisation of the technology of basic and clinical nutrition that it has acquired throughout the years in Japan, and will strengthen its business in India, a country in which significant economic growth and increasingly sophisticated healthcare system are expected. Going forward, under Otsuka Group’s corporate philosophy, ‘Otsuka-people creating new products for better health worldwide’, OPF with its partner will contribute to the betterment of health of the people of India,” said OPF in a statement. 

RECOMMENDED FOR YOU

Japan's Otsuka Pharmaceutical buys out Claris' 20% stake in JV for $ 20 mn

With this, Otsuka to strengthen its basic IV solution and clinical nutrition business in India

With this, Otsuka to strengthen its basic IV solution and clinical nutrition business in India
Ahmedabad-based has entered into a definitive agreement to sell its 20 percent stake in India Pvt Ltd (formerly known as Claris Otsuka Pvt Ltd) to its joint venture partner, Factory Inc (OPF) of Japan, for a total consideration of $ 20 million (about Rs 129 crore). 

In July 2013, had transferred its business in India and emerging markets to the joint venture, Claris Otsuka. As per the terms of agreement, Claris held 20 percent stake in the joint venture, while and & Co Ltd owned 60 percent and 20 percent stake respectively. As part of the deal, two of the five plants of Claris were transferred to joint venture firm. 

Claris Otsuka Private Limited was rechristened as India Private Limited (OPI) on March 1, 2017.

“With this increase in the shareholdings of India, OPF will be able to maximise the utilisation of the technology of basic and clinical nutrition that it has acquired throughout the years in Japan, and will strengthen its business in India, a country in which significant economic growth and increasingly sophisticated healthcare system are expected. Going forward, under Otsuka Group’s corporate philosophy, ‘Otsuka-people creating new products for better health worldwide’, OPF with its partner will contribute to the betterment of health of the people of India,” said OPF in a statement. 
image
Business Standard
177 22

Japan's Otsuka Pharmaceutical buys out Claris' 20% stake in JV for $ 20 mn

With this, Otsuka to strengthen its basic IV solution and clinical nutrition business in India

Ahmedabad-based has entered into a definitive agreement to sell its 20 percent stake in India Pvt Ltd (formerly known as Claris Otsuka Pvt Ltd) to its joint venture partner, Factory Inc (OPF) of Japan, for a total consideration of $ 20 million (about Rs 129 crore). 

In July 2013, had transferred its business in India and emerging markets to the joint venture, Claris Otsuka. As per the terms of agreement, Claris held 20 percent stake in the joint venture, while and & Co Ltd owned 60 percent and 20 percent stake respectively. As part of the deal, two of the five plants of Claris were transferred to joint venture firm. 

Claris Otsuka Private Limited was rechristened as India Private Limited (OPI) on March 1, 2017.

“With this increase in the shareholdings of India, OPF will be able to maximise the utilisation of the technology of basic and clinical nutrition that it has acquired throughout the years in Japan, and will strengthen its business in India, a country in which significant economic growth and increasingly sophisticated healthcare system are expected. Going forward, under Otsuka Group’s corporate philosophy, ‘Otsuka-people creating new products for better health worldwide’, OPF with its partner will contribute to the betterment of health of the people of India,” said OPF in a statement. 

image
Business Standard
177 22